Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy

Journal of Magnetic Resonance Imaging

Volumn 44, Issue 5, 2016, Pages 1107-1115

  Wu, Jia ^a   Gong, Guanghua ^a,b   Cui, Yi ^a   Li, Ruijiang ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TSINGHUA UNIVERSITY   (China)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

breast cancer; DCE MRI; intratumor partitioning; texture analysis; treatment response prediction

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; IMAGE SEGMENTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ALGORITHM; AUTOMATED PATTERN RECOGNITION; BREAST TUMOR; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DRUG MONITORING; FEMALE; IMAGE ENHANCEMENT; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG MONITORING; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MIDDLE AGED; NEOADJUVANT THERAPY; PATTERN RECOGNITION, AUTOMATED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84963553351     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.25279     Document Type: Article

References (39)

1. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019–2027.
2. Smith IC, Heys SD, Hutckeon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456–1466.
3. Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003;78:51–58.
4. Chou C-P, Wu M-T, Chang H-T, et al. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. Acad Radiol 2007;14:561–573.
5. Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83:67–76.
6. Yankeelov TE, Lepage M, Chakravarthy A, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007;25:1–13.
7. Padhani AR, Hayes C, Assersohn L, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results 1. Radiology 2006;239:361–374.
8. Ah-See MLW, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008;14:6580–6589.
9. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006;24:843–847.
10. Li X, Abramson RG, Arlinghaus LR, et al. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer. Invest Radiol 2015;50:195–204.
11. Abramson RG, Li X, Hoyt TL, et al. Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results. Magn Reson Imaging 2013;31:1457–1464.
12. Li X, Arlinghaus LR, Ayers GD, et al. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med 2014;71:1592–1602.
13. Ashraf A, Gaonkar B, Mies C, et al. Breast DCE-MRI kinetic heterogeneity tumor markers: preliminary associations with neoadjuvant chemotherapy response. Transl Oncol 2015;8:154–162.
14. Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL. Radiology 2012;263:663–672.
15. Cho N, Im SA, Park IA, et al. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging. Radiology 2014;272:385–396.
16. Marinovich ML, Sardanelli F, Ciatto S, et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast 2012;21:669–677.
17. Prevos R, Smidt M, Tjan-Heijnen V, et al. Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review. Eur Radiol 2012;22:2607–2616.
18. Johansen R, Jensen LR, Rydand J, et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 2009;29:1300–1307.
19. Ahmed A, Gibbs P, Pickles M, Turnbull L. Texture analysis in assessment and prediction of chemotherapy response in breast cancer. J Magn Reson Imaging 2013;38:89–101.
20. Gatenby RA, Grove O, Gillies RJ. Quantitative imaging in cancer evolution and ecology. Radiology 2013;269:8–15.
21. O'Connor JPB, Rose CJ, Waterton JC, Carano RAD, Parker GJM, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res 2015;21:249–257.
22. Cui Y, Tha KK, Terasaka S, et al. Prognostic imaging biomarkers in glioblastoma: development and independent validation on the basis of multiregion and quantitative analysis of MR images. Radiology 2015:150358.
23. Hylton NM, Gatsonis CA, Rosen MA, et al. Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival—results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 2015:150013.
24. Wu J, Gensheimer MF, Dong X, et al. Robust intra-tumor partitioning to identify high-risk subregions in lung cancer: a pilot study. Int J Radiat Oncol Biol Phys 2016, doi: 10.1016/j.ijrobp.2016.03.018.
25. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2015:151169.
26. Caliñski T, Harabasz J. A dendrite method for cluster analysis. Commun Stat Theory Methods 1974;3:1–27.
27. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B (Methodol) 1996:267–288.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol) 1995:289–300.
29. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008;13(Suppl 3):21–26.
30. Ashraf AB, Daye D, Gavenonis S, et al. Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles. Radiology 2014;272:374–384.
31. Guo W, Li H, Zhu Y, et al. Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data. J Med Imaging 2015;2:041007.
32. Zhu Y, Li H, Guo W, et al. Deciphering genomic underpinnings of quantitative MRI-based radiomic phenotypes of invasive breast carcinoma. Sci Rep 2015;5.
33. Burnside ES, Drukker K, Li H, et al. Using computer-extracted image phenotypes from tumors on breast magnetic resonance imaging to predict breast cancer pathologic stage. Cancer 2015 [Epub ahead of print].
34. Agner SC, Rosen MA, Englander S, et al. Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study. Radiology 2014;272:91–99.
35. Wu J, Aguilera T, Shultz D, et al. Early-stage non-small cell lung cancer: quantitative imaging characteristics of FDG-PET/CT predict distant metastasis. Radiology 2016, doi: 10.1148/radiol.2016151829.
36. Chaudhury B, Zhou M, Goldgof DB, et al. Heterogeneity in intratumoral regions with rapid gadolinium washout correlates with estrogen receptor status and nodal metastasis. J Magn Reson Imaging 2015;42:1421–1430.
37. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778–785.
38. Partridge SC, Vanantwerp RK, Doot RK, et al. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. J Magn Reson Imaging 2010;32:1124–1131.
39. Tateishi U, Miyake M, Nagaoka T, et al. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging—prospective assessment. Radiology 2012;263:53–63.